CoChat

Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans

Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., Foley, J. E. · 2011 · Diabetes, Obesity and Metabolism
Cited by 171

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Inhibition of dipeptidyl peptidase‐4 (DPP‐4) by vildagliptin prevents degradation of glucagon‐like peptide‐1 (GLP‐1) and reduces glycaemia in patients with type 2 diabetes mellitus, with low risk for hypoglycaemia and no weight gain. Vildagliptin binds covalently to the catalytic site of DPP‐4, eliciting prolonged enzyme inhibition. This raises intact GLP‐1 levels, both after meal ingestion and in the fasting state. Vildagliptin has been shown to stimulate insulin secretion and inhibit glucagon secretion in a glucose‐dependent manner. At hypoglycaemic levels, the counterregulatory glucagon response is enhanced relative to baseline by vildagliptin. Vildagliptin also inhibits hepatic glucose production, mainly through changes in islet hormone secretion, and improves insulin sensitivity, as determined with a variety of methods. These effects underlie the improved glycaemia with low risk for hypoglycaemia. Vildagliptin also suppresses postprandial triglyceride (TG)‐rich lipoprotein levels after ingestion of a fat‐rich meal and reduces fasting lipolysis, suggesting inhibition of fat absorption and reduced TG stores in non‐fat tissues. The large body of knowledge on vildagliptin regarding enzyme binding, incretin and islet hormone secretion and glucose and lipid metabolism is summarized, with discussion of the integrated mechanisms and comparison with other DPP‐4 inhibitors and GLP‐1 receptor activators, where appropriate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01414.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 171

Metadata

Authors
Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., & Foley, J. E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-07-26
Volume
13
Issue
9
Pages
775-783
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1805640194
Cited by
171
References
8
FWCI
13.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01414.x
The paper
Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., & Foley, J. E. (2011). Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01414.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.